EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

Aarti Bhatia iD, Ranee Mehra, Jessica Bauman iD, Saad A Khan, Wei Wei, Veronique Neumeister, Teresa Sandoval-Schaefer, R Katherine Alpaugh, Miriam Lango, David L Rimm, John A Ridge, Barbara Burtness

Head & Neck · 2025-09 · 47 (9) · 2373-2382

DOI: 10.1002/hed.28152 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Head & Neck, online erschienen am 01.04.2025. Verfasst von Aarti Bhatia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine (Oncology), Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Cetuximab, Erlotinib Hydrochloride, Head and Neck Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Genentech, Genentech Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prognosis for patients with recurrent/metastatic (R/M) head and neck squamous cell cancer (HNSCC) remains poor. We hypothesized that the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to standard therapy would improve responses by inhibiting nuclear translocation of EGFR and designed a phase 2 trial of chemotherapy, cetuximab, and erlotinib in patients with R/M HNSCC. A 24 patients were enrolled and treated with carboplatin, paclitaxel, and cetuximab administered in 21‐day cycles. Erlotinib was added with cycle 2. The primary end point was the objective response rate (ORR). The secondary end points were toxicity, overall survival (OS) and laboratory correlates. Median age was 65.5 years. Median duration on treatment was 4.6 months. ORR with cycle 1 of treatment was 33.3%, and for cycle 2 and beyond was 58.3%. Median progression‐free survival (PFS) was 6.2 months, and median OS was 10.6 months. Most common treatment‐related adverse events included anemia, neutropenia, skin rash, diarrhea, and hypomagnesemia. Dual EGFR blockade was tolerable and efficacious in this small patient sample. With an ORR of 58.3%, the study met its primary endpoint. PFS and OS were comparable to historical controls. Dual EGFR targeting without the chemotherapy backbone is worthy of further study. Trail Registration: ClinicalTrials.gov identifier: NCT01316757.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCetuximabErlotinib HydrochlorideHead and Neck NeoplasmsNeoplasm Recurrence, LocalSquamous Cell Carcinoma of Head and NeckAgedFemaleHumansMaleMiddle AgedCarboplatinPaclitaxelProgression-Free SurvivalTreatment Outcome

Stichwörter der Autor:innen

EGFR inhibitiondual EGFR targetinghead and neck cancerrecurrent and metastatic diseasetargeted therapies

Substanzen

CarboplatinCetuximabErlotinib HydrochloridePaclitaxel

Autor:innen und Institutionen

  • Department of Internal Medicine (Oncology), Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut, USA.
  • Director of Head and Neck Medical Oncology and Professor of Medicine, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore, Maryland, USA.
  • Division of Head and Neck Medical Oncology, Department of Hematology/Oncology, Hematology/Oncology Fellowship Training Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
  • Associate Professor of Medicine (Oncology), Stanford University and Stanford Cancer Institute, Palo Alto, California, USA.
  • Department of Biostatistics and Internal Medicine (Oncology), Yale School of Public Health and Yale Cancer Center, New Haven, Connecticut, USA.
  • Department of Pathology, Associate Research Scientist in Pathology, Laboratory Director of the Specialized Translational Services Lab at Yale University School of Medicine, New Haven, Connecticut, USA.

ORCID-Profile: Aarti Bhatia, Jessica Bauman

Förderung

  • Genentech
  • Genentech Foundation

Zitieren

APA

Bhatia, A., Mehra, R., Bauman, J., Khan, S. A., Wei, W., Neumeister, V., Sandoval-Schaefer, T., Alpaugh, R. K., Lango, M., Rimm, D. L., Ridge, J. A., & Burtness, B. (2025). Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Head & Neck, 47(9), 2373-2382. https://doi.org/10.1002/hed.28152

Vancouver

Bhatia A, Mehra R, Bauman J, Khan SA, Wei W, Neumeister V, et al. Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Head & Neck. 2025;47(9):2373-2382. doi:10.1002/hed.28152

BibTeX
@article{Bhatia2025,
  author = {Bhatia, Aarti and Mehra, Ranee and Bauman, Jessica and Khan, Saad A and Wei, Wei and Neumeister, Veronique and Sandoval-Schaefer, Teresa and Alpaugh, R Katherine and Lango, Miriam and Rimm, David L and Ridge, John A and Burtness, Barbara},
  title = {Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck},
  journal = {Head & Neck},
  year = {2025},
  volume = {47},
  number = {9},
  pages = {2373--2382},
  doi = {10.1002/hed.28152}
}
Kostenlos starten →